EDAP TMS S.A., each representing One Ordinary Share (EDAP): Price and Financial Metrics
EDAP TMS S.A., each representing One Ordinary Share (EDAP)
Today's Latest Price: $4.63 USD
Updated Oct 23 4:00pm
Add EDAP to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
EDAP Stock Summary
- EDAP's current price/earnings ratio is 84.23, which is higher than 90.1% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for EDAP is currently 36.48, higher than 89.46% of US stocks with positive operating cash flow.
- Over the past twelve months, EDAP has reported earnings growth of 88.01%, putting it ahead of 87.25% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to Edap Tms Sa, a group of peers worth examining would be DESP, AVNW, PERI, VOXX, and VIVO.
- EDAP's SEC filings can be seen here. And to visit Edap Tms Sa's official web site, go to www.edap-tms.com.
EDAP Stock Price Chart Interactive Chart >
EDAP Price/Volume Stats
| Current price | $4.63 | 52-week high | $5.39 |
| Prev. close | $4.64 | 52-week low | $1.46 |
| Day low | $4.60 | Volume | 68,900 |
| Day high | $4.93 | Avg. volume | 109,883 |
| 50-day MA | $4.11 | Dividend yield | N/A |
| 200-day MA | $3.21 | Market Cap | 134.26M |
EDAP TMS S.A., each representing One Ordinary Share (EDAP) Company Bio
EDAP TMS S.A. develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases worldwide. The company was founded in 1979 and is based in Vaulx-en-Velin, France.
EDAP Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $4.63 | $2.55 | -46% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Edap Tms Sa. To summarize, we found that Edap Tms Sa ranked in the 32th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Edap Tms Sa ended up being:
- As a business, EDAP is generating more cash flow than merely 8.09% of positive cash flow stocks in the Healthcare.
- The business' balance sheet reveals debt to be 6% of the company's capital (with equity being the remaining amount). Approximately merely 16.85% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- EDAP's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 42.39% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -47% |
| 1% | -47% |
| 2% | -46% |
| 3% | -46% |
| 4% | -45% |
| 5% | -45% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as EDAP, try OSMT, GILD, IQV, MD, and QDEL.
Loading social stream, please wait...